Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease.

Abstract

This study investigated the association between ischaemia-modified albumin (IMA), a biomarker of cardiac ischaemia, and increases in the levels of intermediate-density lipoprotein (IDL), an atherogenic particle that can cause oxidative stress, in haemodialysis patients with end-stage renal disease (ESRD). Fasting levels of serum IMA and lipids/lipoproteins were analysed in 15 patients and 15 healthy control subjects. There was a close positive correlation between IMA and IDL levels in ESRD patients but no significant correlation between IMA and lipids/lipoproteins in control subjects. This suggests a possible link between the characteristic dyslipoproteinaemia found in ESRD and levels of IMA and, if confirmed in studies with larger sample sizes, may lead to further studies on the potential of the relationship between IMA and IDL as a biomarker in haemodialysis patients with ESRD.

• Authors: K Kotani, S Kimura, E Kinugasa, H Ogata, R Caccavello, N Taniguchi, A Gugliucci
• Journal: The Journal of international medical research (J Int Med Res) Vol. 39 Issue 4 Pg. 1541-5 ( 2011) ISSN: 1473-2300 [Electronic] England
• PMID: 21986159 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Lipoproteins, IDL
• Serum Albumin

Topics

• Case-Control Studies
• Female
• Follow-Up Studies
• Humans
• Ischemia (etiology)
• Kidney Failure, Chronic (complications)
• Lipoproteins, IDL (metabolism)
• Male
• Middle Aged
• Prognosis
• Renal Dialysis (adverse effects)
• Serum Albumin (metabolism)